Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
SOUTHAMPTON, England, June 29 /PRNewswire/ -- Vantia Therapeutics, an
emerging pharmaceutical company developing novel, small molecule drugs
targeting large, underserved medical markets, announces positive results from
a Phase IIa clinical trial of its lead
development compound VA106483 for
ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM)
SEATTLE, Washington, and LEIDEN, The Netherlands, June 18 /PRNewswire/ --
ProFibrix B.V. today announced the start of the company's Phase II clinical
trial for Fibrocaps(TM), the company's lead
topical Hemostat product, with
the successful treatment of the first patients for mild to moderate b...
Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
- Data on BIBW 2992, an Irreversible, Dual EGFR / HER2 Tyrosine Kinase Inhibitor, Suggests Activity in Second-line Treatment of NSCLC Patients with EGFR Activating Mutations - (1,2)
-The First Presentation of Data on BIBF 1120 in Ovarian Cancer-
RIDGEFIELD, Conn., May 14 /PRNewswire/ -- ...
Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
SAN DIEGO, April 13 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) announced today that the United States Patent and Trademark Office issued a production patent (U.S. Patent No. 7,507,564) covering steps used in the manufacture of fidaxomicin , which is currently in i...
Key Protein May Lead to Faster Acting Anti-Depression Drugs
NEW YORK, March 23 /PRNewswire-USNewswire/ -- Research conducted by Nobel laureate Paul Greengard, Medical Director of The Michael Stern Parkinson's Research Center at The Rockefeller University , Dr. Jennifer L. Warner-Schmidt in New York and colleagues in Sweden, demonstrated in the Journal o...
Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions
BALTIMORE, March 17 /PRNewswire/ -- Alba Therapeutics Corporation announced today it will initiate further clinical studies for patients diagnosed with celiac disease with their lead
compound, larazotide acetate. "Our most recent Phase IIb study, the largest trial with an investigational medica...
NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
EMERYVILLE, Calif., March 7 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Alternext: NBY), a mid-stage biopharmaceutical company developing first-in-class, novel, synthetic anti-infective products for the treatment and prevention of a wide range of bacterial, fungal, and viral infe...
Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
Studies Support Potential for Alzheimer's Disease and Other Neurodegenerative Diseases
NEW YORK, March 3 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS) , a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheim...
Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
SOUTH SAN FRANCISCO, Calif., March 2 /PRNewswire-FirstCall/ -- Hana
Biosciences (Nasdaq: HNAB ) today announced that an Independent Data Monitoring
Committee (IDMC) has completed a planned, pre-specified safety review of interim
data from the ongoing pivotal rALLy clinical trial of Marqibo(R...
Positive Data From Lung Study May Lead to First FDA Approved Treatment for Pulmonary Fibrosis
CPF Calls on Manufacturer and FDA to Expedite Review of Pirfenidone as Treatment for PF
SAN JOSE, Calif., Feb. 4 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) is calling this a historic time in the research and treatment of PF, as a pivotal Phase III clinical trial is ...
Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
Company Expects to Deliver Multiple Clinical Milestones throughout the Year; Amigal to Initiate Phase 3 Global Development in Second Quarter; Continued Strong Financial Position
CRANBURY, N.J., Jan. 12 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD ) today announced positive pr...
Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
ROCKVILLE, Md., Jan. 6 /PRNewswire-USNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today that SQ109, its lead
drug candidate for the treatment of tuberculosis (TB), was the first drug approved for evaluation in a newly ...
Soft Contact Lenses Do Not Lead to 'Myopic Creep' in Children, Study Shows
Largest randomized trial of its kind shows no clinically meaningful
difference between contacts and glasses for progression of nearsightedness
JACKSONVILLE, Fla., Nov. 12 /PRNewswire/ -- Soft contact lens wear does
not result in clinically significant acceleration in the development of
Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire/ -- Portola
Pharmaceuticals, a biopharmaceutical company developing innovative drugs
that provide significant advances in cardiovascular and inflammatory
diseases, and cancer, today announced that data relevant to betrixaban, the
company's novel ...
VAI Finding Could Lead to New Drugs for Anxiety, Depression
Researchers determine molecular structure of promising drug target using new method
GRAND RAPIDS, Mich., Oct. 15 /PRNewswire/ -- Researchers in the
Laboratory of Structural Sciences at Van Andel Institute (VAI) have
determined how the hormone corticotrophin releas...
Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
SAN DIEGO, Oct. 7 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc.
(Nasdaq: RDEA ) announced today that a poster entitled "RDEA119, a Potent
and Highly Selective MEK1/2 Inhibitor is Beneficial in Dextran Sulfate
Sodium (DSS) -- induced Chronic Colitis in Mice," was presented at the
Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I
PARIS, October 2 /PRNewswire/ -- Pharmaleads has obtained from the
French Medicine Agency (AFSSAPS) the authorization to perform a single
ascending dose Phase I study with PL37, its lead
compound for oral
treatment of neuropathic pain.
Neuropathic pain is a major chronic pain condition, with...
Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures
PHILADELPHIA, Sept. 30 /PRNewswire-USNewswire/ -- The following is
being released by The Philadelphia AIDS Consortium:
WHO: Parent Organization: The Philadelphia AIDS Consortium in
partnership with its network of eleven (11) community-based organization
sites located throughout the tri-state...
Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
First complement inhibitor to be tested in AMD patients
LOUISVILLE, Ky., Sept. 29 /PRNewswire/ -- Potentia Pharmaceuticals, a
privately held biotechnology company developing medicines for the treatment
of age-related macular degeneration (AMD) announced today that the
InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
- Biotech Begins to Demonstrate Strategy to Expand NHL Marketplace with
Novel Antibody and Speedy DXL Screening Preclinical Development Program -
BRITISH COLUMBIA, Canada, Sept. 16 /PRNewswire-FirstCall/ -- InNexus
Biotechnology Inc. (TSX VENTURE: IXS; OTC Bulletin Board: IXSBF;
Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
SAN DIEGO, Sept. 9 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc.
(Nasdaq: RDEA ) today announced that preclinical data will be presented on
the Company's lead
mitogen-activated ERK kinase (MEK) inhibitor, RDEA119,
at the American College of Gastroenterology Annual Scientific Meeting at
Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
WALTHAM, Mass., Sept. 8 /PRNewswire/ -- Logical Therapeutics, Inc.,
announced today the commencement of its double-blind, randomized,
active-controlled, multinational study of LT-NS001, a novel prodrug, which
is converted in the bloodstream to naproxen, a non-steroidal
anti-inflammatory drug (...
Going Beyond 'Spa Day': Giving Women the Opportunity to Do Something Proactive Which May Lead to Long Term Health Benefits
C'elle Discovers Stem Cells Found in Menstrual Blood May Offer Long-Lasting Therapeutic Effects for Time-Pressed Women
OLDSMAR, Fla., Aug. 25 /PRNewswire/ -- Time. It is a precious
commodity. Yet most women would agree that there never seems to be enough
of it. And the small amount...
Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
SAN DIEGO, Aug. 21 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc.
(Nasdaq: RDEA ) today announced that the Medicines and Healthcare products
Regulatory Agency (MHRA) in the United Kingdom has authorized a Phase 1
study evaluating RDEA594 in normal healthy volunteers. RDEA594 is the
Positive Mosquito Count for West Nile Virus Lead DEP, Southeastern PA Counties to Ramp up Treatment Activities
NORRISTOWN, Pa., Aug. 18 /PRNewswire-USNewswire/ -- Due to an
exceptionally high number of West Nile virus-infected mosquitoes in
southeastern Pennsylvania, the Department of Environmental Protection and
its county partners will be stepping up efforts this week to combat the
New Research Shows One in 200 People Born with DNA Mutation That Can Lead to Devastating, Often Fatal Disease
Mutation Causing Mitochondrial Disease More Common Than Previously
PITTSBURGH, Aug. 11 /PRNewswire-USNewswire/ -- The United Mitochondrial
Disease Foundation (UMDF) today announced landmark research finding that
one in every 200 people has a DNA mutation that could potentially cause...
Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
MEXICO CITY and SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- Ardea
Biosciences, Inc. (Nasdaq: RDEA ) today announced that data was presented
from its completed Phase 2a proof-of-concept monotherapy study of RDEA806,
the Company's novel investigational non-nucleoside reverse transcriptase
Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
SAN DIEGO, July 28 /PRNewswire-FirstCall/ -- Cardium Therapeutics
(Amex: CXM ) announced the appointment of Paul A. Foster, M.D. as Chief
Medical Officer to lead
the Company's late-stage clinical development
activities at Cardium's Tissue Repair Company for the MATRIX Phase 2b
clinical study ...
Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
Study Demonstrates Feasibility and Efficacy of Treating Patients with Primary Liver Cancer
SAN FRANCISCO, and YONGIN-SI, South Korea, July 22 /PRNewswire/ --
Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), and its South
Korean partner Green Cross Corp., announ...
Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
- Once-daily dosing with enteric-coated tablet produced robust antiviral activity -
- RDEA806 was well tolerated during one week of dosing in HIV patients -
SAN DIEGO, June 25 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc.
(Nasdaq: RDEA ) today announced add...
Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
ARLINGTON, Va., June 17 /PRNewswire-FirstCall/ -- Champions
Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the
development of advanced preclinical platforms and tumor specific data to
enhance the value of oncology drugs, today announced that it has begun
Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
Data Presented at ASCO Show 26% Partial Response, 63% Clinical Benefit Incidence
HAYWARD, Calif., June 3 /PRNewswire-FirstCall/ -- Kosan Biosciences
Incorporated (Nasdaq: KOSN ) today announced that its lead
tanespimycin, demonstrated a high lev...
Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
- Primary study objectives include evaluation of safety and tolerability, as well as selection of a recommended dose for Phase 2 trials -
ROCKVILLE, Md., May 30 /PRNewswire-FirstCall/ -- Human Genome Sciences,
Inc. (Nasdaq: HGSI ) today announced that it has initiated dosing in a Phase
Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
SAN CARLOS, Calif., May 30 /PRNewswire-FirstCall/ -- Nektar
Therapeutics (Nasdaq: NKTR ) will host a meeting and Webcast on Monday, June
2, 2008 at 6:30 PM Central Time to discuss the company's lead
program, NKTR-102 (PEG-irinotecan). The Webcast will include a presentation
AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011
AMSTERDAM, May 30 /PRNewswire-FirstCall/ -- Amsterdam Molecular
Therapeutics (Euronext: AMT), a leader in the field of human gene therapy,
today announced that positive interim data from its pivotal clinical trial
with AMT's lead
product Glybera(R) (AMT-011) were presented by the
Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
- RDEA594 Data to Be Presented at the 2008 Annual European Congress of
Rheumatology Organized by the European League Against Rheumatism (EULAR) -
- Initiation of Phase 1 Human Study of RDEA594 Planned in Second Half of 2008 -
SAN DIEGO, May 19 /PRNewswire-Fi...
Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
- IND or foreign regulatory equivalent filing anticipated in 1Q 2009 -
PRINCETON, N.J., May 19 /PRNewswire-FirstCall/ -- Pharmasset, Inc.
(Nasdaq: VRUS ) has nominated PSI-7851 as a lead
development candidate for
the treatment of chronic hepatitis C virus (HCV). PSI-7851 is a proprietary
BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
- First in human clinical data highlight safety profile of BSI-201 in subjects with advanced solid tumors -
BRISBANE, Calif., May 15 /PRNewswire/ -- BiPar Sciences, Inc., a
privately held biopharmaceutical company developing novel cancer therapies,
today announced that data su...
Association of Clinical Research Organizations (ACRO) to Help Lead Clinical Trials Transformation Initiative
ACRO to collaborate with key stakeholders on efforts to enhance the
clinical research enterprise
WASHINGTON, May 6 /PRNewswire-USNewswire/ -- The Association of
Clinical Research Organizations (ACRO), which represents the clinical
outsourcing industry to regulators, biopharmaceutical clien...
ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
ESBA105 Penetrates all Segments of the Eye via Topical Eye Drops
ZURICH, Switzerland, April 24 /PRNewswire/ -- ESBATech AG, a leading
developer of antibody fragment therapeutics, today announced the initiation
of Phase I clinical development of the company's lead